Bausch & Lomb Corp 8K

Bausch + Lomb reported stronger-than-expected Q1 2026 results and raised its full-year 2026 revenue and adjusted EBITDA guidance on the back of solid segment growth and improved profitability.

On April 29, 2026, Bausch + Lomb Corporation reported strong first‑quarter 2026 results with revenue of $1.244 billion, up 9% year-over-year (6% in constant currency), driven by growth across Vision Care, Surgical, and Pharmaceuticals, including double‑digit gains from dry eye drugs MIEBO and XIIDRA, while GAAP net loss narrowed to $71 million and adjusted EBITDA rose to $189 million ($200 million excluding acquired IPR&D). Based on this performance and increased foreign exchange tailwinds, the company raised its full‑year 2026 revenue guidance to a range of $5.420–$5.520 billion (5.3–7.2% constant currency growth) and increased its adjusted EBITDA excluding acquired IPR&D outlook to $1.010–$1.060 billion, citing ongoing operational efficiencies, AI-driven productivity initiatives, and continued investment in its R&D pipeline, including recent regulatory submissions for LUMIFY NXT and seeLYRA. The company also highlighted improved operating income versus the prior-year quarter, positive operating cash flow of $32 million, and provided details for an earnings conference call with investors and analysts.

Filing Facts

CIK

1860742

Ticker

-

Form

8K

Source Type

sec

Accession

0001860742-26-000060

Alert Tier

7